Journal article
Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective
Abstract
OBJECTIVE: The study evaluates the cost-effectiveness of secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, vs currently licensed biologic treatments in patients with active psoriatic arthritis (PsA) from a Canadian healthcare system perspective.
METHODS: A decision analytic semi-Markov model evaluated the cost-effectiveness of secukinumab 150 mg and 300 mg compared to subcutaneous biologics …
Authors
Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
Journal
Journal of Medical Economics, Vol. 21, No. 2, pp. 163–173
Publisher
Taylor & Francis
Publication Date
February 1, 2018
DOI
10.1080/13696998.2017.1384737
ISSN
1369-6998
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, PsoriaticBiological ProductsBiosimilar PharmaceuticalsCanadaCost-Benefit AnalysisDecision Support TechniquesDrug Administration ScheduleDrug CostsFemaleFollow-Up StudiesHumansInjections, SubcutaneousMaleMarkov ChainsQuality-Adjusted Life YearsSeverity of Illness IndexTime FactorsTreatment Outcome